secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001370053-25-000097
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity
--------------------------------------------------------------------------------

- Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.
- Anaptys has repurchased 3,443,188 shares (11.2% of shares outstanding) under the plan to date.
- Company expects ~$300M cash end-2025, including anticipated $75M commercial milestone from GSK on Jemperli reaching $1B sales.
- Plan expires March 31, 2026; repurchases depend on market conditions and regulatory limitations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/0001370053-25-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/anab-20251121.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer